Objective: To assess the prevalence of nonmedical prescription opioid use (NMPOU) in the Canadian general adult population in the context of rising overall prescription opioid (PO) consumption and related problems in North America.
I n recent years, increasing attention has been given to the phenomenon of NMPOU and its consequences in North America. 1, 2 Specifically in the United States, epidemiologic data have shown that incidence and prevalence rates of NMPOU, as well as associated morbidity and mortality, have substantially risen since the early 1990s. 1, 3 For example, annual initiates of NMPOU increased from 573 000 in 1990 to more than 2.2 million in 2008. 4, 5 In 1997, 1.9% of the US general adult population reported NMPOU in the past year; this figure rose to 4.8% in 2008. 5, 6 From 2004 to 2006, PO-related emergency department visits increased 43% from 172 726 to 247 669, 7 and annual PO-related accidental overdose deaths doubled to about 5528 between 1999 and 2002. 8 For Canada, it has been hypothesized that prevalence levels of NMPOU have similarly increased; however, no epidemiologic data for the general population have been available until now. 2 Assumptions of high NMPOU levels were made on the following basis: First, NMPOU has widely been assumed to be a function of overall medical use levels, and the United States and Canada are distinct lead countries in (per capita) PO consumption worldwide. 2, [9] [10] [11] Specifically, overall PO consumption levels in these 2 countries have doubled in the past decade alone. 1, 2, 11 Second, there have been indicators of substantial local spikes or longitudinal increases of PO-related mortality in regions (for example, Ontario) across Canada, suggesting that high and increasing PO consumption levels have translated into elevated mortality rates. 12, 13 Similar to developments in the United States, admissions to substance use treatment programs for problematic PO use have doubled in Ontario between 2004 and 2009. 14 Our study assesses and contextualizes the prevalence of NMPOU in the Canadian general adult population based on data from the recently implemented CADUMS.
Methods
The CADUMS represents the first pan-Canadian population survey that included measurement of both medical and nonmedical PO use in Canada. CADUMS is an ongoing cross-sectional, monthly random digit dialing, 2-stage probability telephone survey representative of the general Canadian population, aged 15 years and older, stratified by 10 provinces. Within each of the provincial strata, a probabilistic sample of telephone numbers was selected via random digit dialing. Within selected households, 1 respondent aged 15 years and older was chosen randomly based on the most recent birthday. A minimum of 12 call-backs were placed to unanswered numbers; all households who declined participation were re-contacted to secure maximum participation. Results presented were based on an overall sample of 16 672 respondents, surveyed from April and December of 2008, with a response rate of 43.5%. 15 The prevalence of NMPOU was computed by combining the responses for participants who reported that they had used POs in the past year, and who further responded that they had used POs on at least 1 occasion to get high, or that any of their POs were obtained from a prescription written for someone else, or were bought from someone else, or were obtained from any other source. Calculations were done by Stata 10 software (StataCorp, College Station, TX) on the basis of the original CADUMS dataset provided by Health Canada. Missing data (that is, do not know answers, responses, and refusals) were excluded from analyses, limiting results to valid responses. All statistical tests were corrected for the sampling design. The percentages reported were based on the weighted sample and can be considered representative of the Canadian adult population. CADUMS was implemented with ethics approval from relevant institutions under the auspices of Health Canada.
Results
The rate of any past-year PO use in the CADUMS was 21.6% (95% CI 20.4% to 22.9%). 16 The corresponding prevalence of NMPOU was computed at 0.5% (95% CI 0.3% to 0.8%). PO use was significantly higher among women (24.2%; 95% CI 22.6% to 25.9%) than men (18.9%; 95% CI 17.2% to 20.8%), and highest in the age group of 25 to 54 years (23.0%; 95% CI 21.3% to 24.8%). NMPOU was similar among men and women (0.6%; 95% CI 0.3% to 0.9% and 0.5%, 95% CI 0.2% to 0.9%, respectively), and highest in the age group of 15 to 24 years (1.2%; 95% CI 0.3% to 2.1%).
Discussion
While the past-year prevalence level of any PO use in the CADUMS sample-that is, about 1 in 5 Canadians-appears high, it is not surprising given the high volume consumption levels of PO medications in Canada. 11 Conversely, the NMPOU rate found appears to be extremely-and probably unrealistically-low, for several reasons. First, the NMPOU prevalence found in this Canadian survey seems inconsistent with the range of other PO use and problem indicators available for North America, and specifically with comparable NMPOU indicators reported for the United States. Concretely, while the overall proportional (per capita) volume of PO consumption in the United States is about double than in Canada, and estimated key rates of morbidity (for example, treatment admissions) and mortality (for example, overdose deaths) are similar, the prevalence of NMPOU found in the CADUMS (0.5%) is only about one-tenth of the NMPOU prevalence (4.8%) found in the NSDUH for the US general population in 2008. 5 The discrepancy might even be larger as the NSDUH includes respondents aged 12 years and older, and NMPOU among young teenagers is most likely low. On this basis, the extensive difference in the NMPOU prevalence estimates between Canada and the US general populations seem counterintuitive and questionable.
There are several possible explanations for this difference. First, evidently, the survey data might reflect vastly differential realities of NMPOU in Canada and the United States, respectively, although we have challenged the likelihood of this scenario above. The second is that possible differences might be rooted in methodological differences regarding the surveys' operationalization of NMPOU. 17 While the CADUMS and NSDUH surveys were based on large samples, there are crucial differences in sampling, response rates, and relevant question items. For example, while the CADUMS operationalized NMPOU as described above, the most recent NSDUH survey asks about "any prescription pain reliever that was not prescribed for you or that you took only for the experience or feeling it caused." 5, p 195 Thus both, the CADUMS and the NSDUH, rely on-however, rather different-subjective indicators for NMPOU. Psychoactive or intoxicating effects from PO medications are experienced or felt differently by people. Such concepts are also value-laden and may lead respondents to negatively or untruthfully respond to such questions as it may be challenging for them to imagine or remember such sources. 18 Further, the NSDUH is not a telephone survey such as the CADUMS, but respondents are shown individual visual images of different POs. This may aid recall accuracy and result in more reliable data for the NSDUH survey. On this basis, the specific formulation of the respective NSDUH items may lead to an overestimation, whereas the wording of the CADUMS items may have led to an underestimation of NMPOU.
Another possible reason influencing the low NMPOU rate in the CADUMS may be its comparably low response rate. While sampling was probabilistic, thus allowing, in principle, for results representative of the general population, there is a higher likelihood that people engaging in more deviant behaviour such as NMPOU may be nonresponders with a response rate as low as 40%. 19 In contrast, the NSDUH's response rates have been considerably higher, specifically about 90% for households, and almost 75% on the individual level, in 2008. 5 To systematically develop and establish improved NMPOU measures, several considerations and steps are required. First, such measurements should be embedded in a public health framework. It is of limited relevance for public health whether someone once in the past year nonmedically used a PO analgesic obtained from a family member owing to a severe headache, as emphasized by the recent Canadian National Thematic Workshop on this topic. Thus survey questions should be formulated to exactly measure what has been formally defined as NMPOU. 20 These formulations should also include clear measurements of frequency, patterns, and motivations. 21 Once developed, different possible operationalizations have to be cognitively tested and compared, 22 and the most promising options should be piloted to assess their impact on prevalence estimates as well as their convergent and discriminative validity. 23 At the end of this process, better and validated measurement tools for understanding the NMPOU phenomenon and allowing the development of targeted interventions will be available. While this will take time to accomplish, it would be desirable if lead investigators of current surveys examining NMPOU in Canada would connect and agree on using one-most meaningful-set of existent NMUPO question items in the interest of intersurvey comparability in the short term.
In sum, accurate prevalence estimates of NMPOU in general populations are essential for epidemiology and evidencebased interventions concerning the growing public health problem of NMPOU. 24 The CADUMS data on NMPOU, especially in comparison with US data, raise considerable questions about the validity of estimates for Canada. The discrepancies observed underscore the urgent need for concerted efforts to systematically develop, validate, and standardize survey question items for NMPOU. Conclusions : Les données de l'ESCCAD indiquent un taux extrêmement faible de PNMUO, surtout compte tenu des niveaux d'utilisation générale de PO, des autres problèmes liés à l'utilisation de PO, et des niveaux de PNMUO estimés dans la population générale américaine, où l'utilisation de PNMUO est estimée 10 fois plus élevée qu'au Canada. La construction des items de l'enquête sur les PNMUO et les taux de réponse semblent influencer fortement et potentiellement compromettre les données de l'enquête sur les PNMUO. Les données existantes sur les PNMUO et les méthodes d'enquête doivent être validées pour cet indicateur important au Canada, où l'utilisation croissante de PO et les niveaux des problèmes ont été reconnus constituer un problème de santé publique significatif et en hausse.
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